Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

During 12-week post-treatment period, nimacimab plus semaglutide blunts weight regain compared to semaglutide alone in subset analysisSAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will present a late-breaking oral presentation at ObesityWeek 2025 on November 7, 2025, in Atlanta, Georgia. The presentation w ...